Results 141 to 150 of about 103,228 (328)

Lack of Inotropic Effects of Neuropeptide Y in Human Myocardium

, 1989
Martin C. Michel, S Claudia Wirth, Hans‐Reinhard Zerkowski, Alan S. Maisel, Harvey Motulsky   +4 more
openalex   +1 more source

Altered activity within the social behavior neural network in adolescent rats following prenatal alcohol exposure and/or early‐life adversity

Alcohol, Clinical and Experimental Research, Volume 49, Issue 7, Page 1445-1458, July 2025.
Prenatal alcohol exposure (PAE) and early‐life adversity (ELA) independently and interactively disrupted neural activity within the social behavior network in adolescent rats, with age‐ and sex‐specific effects. PAE primarily dampened amygdala activity, while ELA altered medial prefrontal cortex responses. These findings reveal how different early‐life
Parker J. Holman, Linda Ellis, Amanda Chao, Cecilia Mitchell, Charlis Raineki, Joanne Weinberg   +5 more
wiley   +1 more source

Effects of glucagon‐like peptide 1 receptor agonists on testicular dysfunction: A systematic review and meta‐analysis

Andrology, EarlyView.
Abstract Background Hypogonadism and infertility are two conditions that are heavily affected by overweight and obesity in the male patient. Glucagon‐like peptide 1 agonists (GLP‐1RAs) are a recently introduced class of antidiabetic drugs with powerful weight‐loss effect; this may induce an indirect positive effect on the testicular function ...
Gianmaria Salvio, Alessandro Ciarloni, Nicola Ambo, Monia Bordoni, Michele Perrone, Silvia Rossi, Giancarlo Balercia   +6 more
wiley   +1 more source

Effects of Antihypertensive Drugs on Sympathetic Vascular Control in Relation to Neuropeptide Y

, 1987
Jan M. Lundberg, J. Pernow, A. Franco-Cereceda, A. Rudehill   +3 more
openalex   +1 more source

Cannabidiol dose dependently reduces alcohol intake in mice via a non‐5‐HT1A receptor mechanism: Exploration of other potential receptor targets

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Binge drinking is a risky pattern of alcohol intake and a major predictor of alcohol use disorder (AUD). Current AUD medications have limited efficacy and poor patient compliance, calling for more effective therapeutics.
Connie J. Badolato, Erin A. Lynch, Jonathon C. Arnold, Iain S. McGregor, Michael T. Bowen   +4 more
wiley   +1 more source

Isolation and structure of the second of two major peptide products from the precursor to an anglerfish peptide homologous to neuropeptide Y.

, 1986
Philip Andrews, Jack E. Dixon
openalex   +1 more source

Inhibition of neuropeptide Y‐induced potentiation of noradrenaline‐induced vasoconstriction by PP56 (d‐myo‐inositol 1,2,6‐tris‐phosphate) [PDF]

, 1992
M. Adamsson, Bo Fallgren, Lars Edvinsson
openalex   +1 more source

A GLP‐1R/Y1 receptor/Y2 receptor triple agonist decreases fentanyl‐evoked dopamine release in the nucleus accumbens and attenuates fentanyl taking and seeking in rats

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Emerging literature indicates that simultaneously targeting glucagon‐like peptide‐1 receptors (GLP‐1Rs) and neuropeptide Y receptors (Y1/Y2) may represent a new pharmacotherapeutic approach to treating opioid use disorder (OUD).
Antonia Caffrey, Enzo Lavecchia, Kylie S. Chichura, Matthew R. Hayes, Robert P. Doyle, Heath D. Schmidt   +5 more
wiley   +1 more source

Beyond synapses: cytoplasmic connections in brain function and evolution

Biological Reviews, EarlyView.
ABSTRACT Following Ramón y Cajal's groundbreaking contributions to the identification of synapses, research in neuroscience predominantly focused on their pivotal role in neural communication (the neuron doctrine), overlooking an intriguing possibility suggested by Golgi of non‐synaptic interactions among neural cells.
Malalaniaina Rakotobe, Chiara Zurzolo
wiley   +1 more source

Neurobeachin (NBEA) is a novel gene associated with GLP‐1 receptor agonist associated weight loss

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Nearly 42% of adults in the United States have obesity, a significant risk factor for many cardiometabolic diseases and cancers. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are promising interventions for weight loss, but their efficacy varies significantly across individuals.
Arshiya Mariam‐Smith, Joseph H. Breeyear, Noah J. Daniels, Kevin M. Pantalone, Marcio L. Griebeler, Alison A. Motsinger‐Reif, Daniel M. Rotroff   +6 more
wiley   +1 more source